Cerecor Turns The LIGHT Back On As Avalo, With PRV Haul In Sight
Anti-LIGHT Focus On IBD Expanded To COVID-19 ARDS
Executive Summary
The former Cerecor boasts four pipeline assets that could yield US FDA priority review vouchers. Having divested CNS assets, the renamed firm will focus on IBD with first-in-class anti-LIGHT candidate, plus immunology and rare diseases.